- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03187626
Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis (RHIBOT)
June 26, 2021 updated by: Assistance Publique - Hôpitaux de Paris
Short-term Efficacy of a Single Ultrasound-guided Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis: a Randomized Controlled Double-blind Pilot Study
The primary purpose of this study is to determine whether a single ultrasound-guided intra-articular injection of botulinum toxin A associated to splinting is effective in reducing pain at 3 months in base-of-thumb osteoarthritis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Base-of-thumb osteoarthritis is a common condition affecting middle-age persons.
Base-of-thumb osteoarthritis induces pain and hand-specific limitations in activities.
For short and midterm effects, therapeutic options usually include splinting, exercise therapy and intra-articular injections of glucocorticoids or hyaluronic acid.
However, evidence of efficacy of intra-articular therapies in base-of-thumb osteoarthritis and international guidelines are inconsistent.
Recently, the use of intra-articular botulinum toxin A as a pain killer has raised intense interest.
The exact mechanisms of pain modulation by botulinum toxin A in osteoarthritis are unclear.
It has been suggested that botulinum toxin A could directly reduce peripheral sensitization and indirectly reduce central sensitization.
Indeed, recent studies suggest an inhibitory role of botulinum toxin A on the release of mediators involved in nociception, such as P substance, calcitonin gene-related peptide and glutamate.
Open and randomized controlled trials of botulinum toxin A in knee osteoarthritis support short to mid-term positive clinical effects on pain.
However, no study has reported results for base-of-thumb osteoarthritis
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75014
- Assistance Publique - Hôpitaux de Paris, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Hôpital Cochin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Pain intensity on a self-administered 11-point pain numeric rating scale ≥ 30
- Pain involving the base-of-thumb
- X-ray evidence of base-of-thumb osteoarthritis with at least 2 of the 4 following items involving the trapeziometacarpal joint : osteophytes, joint space narrowing, subchondral bone sclerosis or subchondral cysts
- 1990 American College of Rheumatology classification criteria for hand osteoarthritis adapted to base-of-thumb osteoarthritis
- Medical examination
- Written consent
- Health insurance
- For women of childbearing age, a negative urinary pregnancy test
Exclusion Criteria:
- History of thumb surgery
- History of inflammatory or crystal-associated rheumatic disease
- Neurological disorders involving the hands other than carpien canal syndrom
- Collagen disorders involving the hands : Dupuytren, Marfan or Ehlers-Danlos diseases
- Osteoarthritis predominating at the scaphotrapezial joint on X-Ray
- Hand or wrist trauma ≤ 2 months
- Hand or wrist intra-articular injections ≤ 2 months
- Contra-indication to botulinum toxin A injection or to splinting
- Cognitive or behavioral disorders making the assessment impossible
- Participant unable to speak, read and write french
- Bilateral BTOA without predominant symptomatic side
- Pregnancy and breast feeding
- Persons referred to in Articles L 1121-5; 6; 8; 9 of the Public Health Code (protected minors or adults, guardianship or trusteeship, etc.)
- Patient with epilepsy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intra-articular botulinum toxin A and splinting
Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
|
Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Other Names:
|
Active Comparator: Intra-articular saline and splinting
Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
|
Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in base-of-thumb pain 3 months post-injection
Time Frame: 3 months post injection
|
Mean change from baseline in average base-of-thumb pain intensity in the previous 48 hrs on a self-administered 11-point pain numeric rating scale (0 no pain - 100 maximal pain)
|
3 months post injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in base-of-thumb pain 1 month post-injection
Time Frame: 1 month post injection
|
Mean change from baseline in average base-of-thumb pain intensity in the previous 48 hrs on a self-administered 11-point pain numeric rating scale (0 no pain - 100 maximal pain)
|
1 month post injection
|
Change in base-of-thumb pain 6 months post-injection
Time Frame: 6 months post injection
|
Mean change from baseline in average base-of-thumb pain intensity in the previous 48 hrs on a self-administered 11-point pain numeric rating scale (0 no pain - 100 maximal pain)
|
6 months post injection
|
Change in hand function 3 months post-injection
Time Frame: 3 months post injection
|
Mean change from baseline in average hand-specific limitations in activities in the previous 2 weeks on the self-administered Cochin Hand Function Scale (0 no limitations - 90 maximal limitations)
|
3 months post injection
|
Change in hand function 6 months post-injection
Time Frame: 6 months post injection
|
Mean change from baseline in average hand-specific limitations in activities in the previous 2 weeks on the self-administered Cochin Hand Function Scale (0 no limitations - 90 maximal limitations)
|
6 months post injection
|
Change in patient's global assessment 3 months post-injection
Time Frame: 3 months post-injection
|
Mean change from baseline in patient's global assessment on a self-administered 11-point numeric rating scale (0 worst possible - 100 best possible)
|
3 months post-injection
|
Change in patient's global assessment 6 months post-injection
Time Frame: 6 months post-injection
|
Mean change from baseline in patient's global assessment on a self-administered 11-point numeric rating scale (0 worst possible - 100 best possible)
|
6 months post-injection
|
Percentage of OARSI responders 3 months post-injection
Time Frame: 3 months post-injection
|
OARSI response is defined as an improvement in pain (0 to 100 numeric rating scale) or in function (0 to 90 Cochin Hand Function Scale) ≥ 50% and absolute change ≥ 20/100 on pain numeric rating scale or ≥ 9/90 on Cochin Hand Function Scale respectively , or improvement in at least 2 of the 3 following items: 1/ pain ≥ 20% and absolute change ≥ 10/100, 2/ function ≥ 20% and absolute change ≥ 9/90, 3/ patient's global assessment (0 to 100 numeric rating scale) ≥ 20% and absolute change ≥ 10/100
|
3 months post-injection
|
Percentage of OARSI responders 6 months post-injection
Time Frame: 6 months post-injection
|
OARSI response is defined as an improvement in pain (0 to 100 numeric rating scale) or in function (0 to 90 Cochin Hand Function Scale) ≥ 50% and absolute change ≥ 20/100 on pain numeric rating scale or ≥ 9/90 on Cochin Hand Function Scale respectively , or improvement in at least 2 of the 3 following items: 1/ pain ≥ 20% and absolute change ≥ 10/100, 2/ function ≥ 20% and absolute change ≥ 9/90, 3/ patient's global assessment (0 to 100 numeric rating scale) ≥ 20% and absolute change ≥ 10/100
|
6 months post-injection
|
Analgesics consumption at 3 months
Time Frame: from injection to 3 months post-injection
|
Self-reported consumption of analgesics (non-opioid, weak and strong opioids) using a self-administered 4-class scale (never; several times a month; several times a week; daily)
|
from injection to 3 months post-injection
|
Analgesics consumption at 6 months
Time Frame: from 3 to 6 months post-injection
|
Self-reported consumption of analgesics (non-opioid, weak and strong opioids) using a self-administered 4-class scale (never; several times a month; several times a week; daily)
|
from 3 to 6 months post-injection
|
Non-steroidal anti-inflammatory drugs consumption at 3 months
Time Frame: from injection to 3 months post-injection
|
Self-reported consumption of non-steroidal anti-inflammatory drugs using a self-administered 4-class scale (never; several times a month; several times a week; daily)
|
from injection to 3 months post-injection
|
Non-steroidal anti-inflammatory drugs consumption at 6 months
Time Frame: from 3 to 6 months post-injection
|
Self-reported consumption of non-steroidal anti-inflammatory drugs using a self-administered 4-class scale (never; several times a month; several times a week; daily)
|
from 3 to 6 months post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: François RANNOU, MD, PhD, AP-HP , université Paris Descartes
- Principal Investigator: Christelle NGUYEN, MD, PhD, AP-HP, université Paris Descartes
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 29, 2018
Primary Completion (Actual)
February 16, 2021
Study Completion (Actual)
April 23, 2021
Study Registration Dates
First Submitted
June 13, 2017
First Submitted That Met QC Criteria
June 13, 2017
First Posted (Actual)
June 15, 2017
Study Record Updates
Last Update Posted (Actual)
June 30, 2021
Last Update Submitted That Met QC Criteria
June 26, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- P160404
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Base-of-thumb Osteoarthritis
-
Indiana Hand to Shoulder CenterCTM BiomedicalEnrolling by invitationOsteoarthritis | Osteoarthritis Thumb Base Joint | Carpometacarpal Osteoarthritis | ThumbUnited States
-
Loci OrthopaedicsNorth American Science Associates Ltd.Active, not recruitingOsteoarthritis Thumb Base JointBelgium
-
Hacettepe UniversityActive, not recruitingThumb Osteoarthritis | Thumb Injury | Thumb Fracture | Thumb LacerationTurkey
-
University of AlbertaRecruitingThumb Osteoarthritis | Osteoarthritis of the Carpometacarpal JointCanada
-
University of MinnesotaRecruitingThumb Carpometacarpal Osteoarthritis | Thumb Basal Joint OsteoarthritisUnited States
-
Töölö HospitalRecruitingQuality of Life | Arthritis | Arthropathy | Thumb OsteoarthritisFinland
-
Schulthess KlinikCompletedJoint Instability | Osteoarthritis Thumb | Arthrosis of First Carpometacarpal JointSwitzerland
-
Schulthess KlinikLeiden University Medical CenterCompletedOsteoarthrosis of the Carpometacarpal Joint of the ThumbSwitzerland
-
Columbia UniversityAmerican Society for Surgery of the Hand; Arthritis FoundationRecruitingOsteoarthrosis of the Carpometacarpal Joint of the ThumbUnited States
-
University of UtahCompletedOsteoarthrosis of the Carpometacarpal Joint of the ThumbUnited States
Clinical Trials on botulinum toxin A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Walter Reed Army Medical CenterUnknown
-
YangHuiUnknown
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
University of MalayaCompleted
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic CarcinomaUnited States